News
IMRN
1.880
-1.53%
-0.029
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
Barchart · 1d ago
Weekly Report: what happened at IMRN last week (1111-1115)?
Weekly Report · 5d ago
Weekly Report: what happened at IMRN last week (1104-1108)?
Weekly Report · 11/11 12:02
Weekly Report: what happened at IMRN last week (1028-1101)?
Weekly Report · 11/04 11:58
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/29 12:08
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/29 10:12
Weekly Report: what happened at IMRN last week (1021-1025)?
Weekly Report · 10/28 11:48
Weekly Report: what happened at IMRN last week (1014-1018)?
Weekly Report · 10/21 11:44
Immuron reports Q3 sales of Travelan up 13% vs. Q2
TipRanks · 10/15 10:10
Immuron Announces Sales (Unaudited) Of Travelan A$1.5M, Up 13% Prior Quarter, An OTC Immune Supplement Targeting Pathogenic Bacteria And Toxins Produced In The Gastrointestinal Tract
Benzinga · 10/15 10:09
Immuron Travelan® continued strong sales growth
Barchart · 10/15 05:00
Weekly Report: what happened at IMRN last week (1007-1011)?
Weekly Report · 10/14 12:19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/14 12:08
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/11 12:07
Weekly Report: what happened at IMRN last week (0930-1004)?
Weekly Report · 10/07 12:06
Immuron says NMRC completes interim analysis for evaluation in Campylobacter
TipRanks · 10/05 09:06
Following A Discussion With The US Naval Medical Research Command (NMRC), Immuron Announced That The NMRC Has Completed The Interim Analysis For The Clinical Evaluation Of A New Oral Therapeutic Targeting Campylobacter And Enterotoxigenic Escherichia Coli
Benzinga · 10/04 10:33
Immuron’s Compliance Crucial: Sarbanes-Oxley Act Adherence Key to Financial Stability and Investor Trust
TipRanks · 10/04 06:00
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
Barchart · 10/04 05:30
More
Webull provides a variety of real-time IMRN stock news. You can receive the latest news about Immuron Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IMRN
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.